Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Publication|Articles|April 24, 2026
Supplements and Featured Publications
- Continuous Glucose Monitoring at Hospital Discharge: Evidence, Implementation, and Value for Health Systems
Continuous Glucose Monitoring at Hospital Discharge: Evidence, Implementation, and Value for Health Systems
Listen
0:00 / 0:00
Advertisement
This resource was independently developed by AJMC and funded by an Independent Medical Education Grant from DexCom, Inc.
This actionable resource explores the rising need for continuous glucose monitoring (CGM) at hospital discharge for patients with diabetes and discusses how health systems can more effectively implement CGM at key transition points in care.
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.
Advertisement
Advertisement